These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 31101085)

  • 1. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.
    Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH
    BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin.
    Otabil KB; Ankrah B; Bart-Plange EJ; Donkoh ES; Avarikame FA; Ofori-Appiah FO; Babae TN; Kudzordzi PC; Darko VA; Ameyaw J; Bamfo JG; Sakibu RA; Antwi-Berko D; Fodjo JNS; Basáñez MG; Schallig HDFH; Colebunders R
    Infect Dis Poverty; 2023 Aug; 12(1):75. PubMed ID: 37587500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana.
    Otabil KB; Basáñez MG; Ankrah B; Opoku SA; Kyei DO; Hagan R; Ababio R; Bart-Plange EJ; Babae TN; Kudzordzi PC; Darko VA; Bamfo JG; Ameyaw J; Raji AS; Hadermann A; Schallig HDFH; Colebunders R
    Trop Med Int Health; 2023 Nov; 28(11):844-854. PubMed ID: 37846505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study.
    Osei-Atweneboana MY; Eng JK; Boakye DA; Gyapong JO; Prichard RK
    Lancet; 2007 Jun; 369(9578):2021-2029. PubMed ID: 17574093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onchocerciasis situation in the Tukuyu focus of southwest Tanzania after ten years of ivermectin mass treatment.
    Mweya CN; Kalinga AK; Kabula B; Malley KD; Ruhiso MH; Maegga BT
    Tanzan Health Res Bull; 2007 Sep; 9(3):174-9. PubMed ID: 18087895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of parasitological indicators and morbidity burden of onchocerciasis after years of successive implementation of mass distribution of ivermectin in selected communities of Yeki and Asosa districts, Ethiopia.
    Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
    BMC Public Health; 2020 Aug; 20(1):1233. PubMed ID: 32787813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does onchocerciasis transmission take place in hypoendemic areas? a study from the North Region of Cameroon.
    Katabarwa MN; Eyamba A; Chouaibou M; Enyong P; Kuété T; Yaya S; Yougouda A; Baldiagaï J; Madi K; Andze GO; Richards F
    Trop Med Int Health; 2010 May; 15(5):645-52. PubMed ID: 20345553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after 15 years of mass drug administration with ivermectin in the Tombel Health District, Cameroon.
    Nyagang SM; Cumber SN; Cho JF; Keka EI; Nkfusai CN; Wepngong E; Tsoka-Gwegweni JM; Fokam EB
    Pan Afr Med J; 2020; 35():107. PubMed ID: 32637005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
    Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
    Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the suspension of mass drug administration during the COVID-19 pandemic on onchocerciasis prevalence in the Bandjoun and Massangam health districts, West Region of Cameroon.
    Shintouo CM; Shey RA; Yengo BN; Yaah NE; Teh RN; Ngwese RA; Ayong L; Vanhamme L; Souopgui J; Ghogomu SM; Njemini R
    Acta Trop; 2023 Oct; 246():106999. PubMed ID: 37549841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
    Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection.
    Vieira JC; Cooper PJ; Lovato R; Mancero T; Rivera J; Proaño R; López AA; Guderian RH; Guzmán JR
    BMC Med; 2007 May; 5():9. PubMed ID: 17521449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
    Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
    Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point prevalence mapping reveals hotspot for onchocerciasis transmission in the Ndikinimeki Health District, Centre Region, Cameroon.
    Aza'ah RA; Sumo L; Ntonifor NH; Bopda J; Bamou RH; Nana-Djeunga HC
    Parasit Vectors; 2020 Oct; 13(1):519. PubMed ID: 33066826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential susceptibility of Onchocerca volvulus microfilaria to ivermectin in two areas of contrasting history of mass drug administration in Cameroon: relevance of microscopy and molecular techniques for the monitoring of skin microfilarial repopulation within six months of direct observed treatment.
    Abong RA; Amambo GN; Chounna Ndongmo PW; Njouendou AJ; Ritter M; Beng AA; Esum ME; Deribe K; Fru-Cho J; Fombad FF; Nji TM; Enyong PI; Poole CB; Pfarr K; Hoerauf A; Carlow CKS; Wanji S
    BMC Infect Dis; 2020 Oct; 20(1):726. PubMed ID: 33008333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Reevaluation of the Tolerability and Effects of Single-Dose Ivermectin Treatment on Onchocerca volvulus Microfilariae in the Skin and Eyes in Eastern Ghana.
    Opoku NO; Gyasi ME; Doe F; Lew D; Hong AR; Chithenga S; Fischer PU; King CL; Weil GJ
    Am J Trop Med Hyg; 2021 Nov; 106(2):740-745. PubMed ID: 34844204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin.
    Kamga HL; Shey DN; Assob JC; Njunda AL; Nde Fon P; Njem PK
    Pan Afr Med J; 2011; 10():34. PubMed ID: 22187616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Field-Based Evidence of Single and Few Doses of Annual Ivermectin Treatment Efficacy in Eliminating Skin Microfilaria Load after a Decade of Intervention.
    Osue HO
    Ethiop J Health Sci; 2017 Mar; 27(2):129-138. PubMed ID: 28579708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteinuria and onchocerciasis in an endemic area in Cameroon under community-based treatment with ivermectin.
    Ebong CE; Alemnji GA; ; Ashuntantang G; Asonganyi T
    Trop Doct; 2007 Jul; 37(3):156-8. PubMed ID: 17716503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge, attitude and practice of community drug distributors' about onchocerciasis and community directed treatment with ivermectin in Quara district, North Western Ethiopia.
    Weldegebreal F; Medhin G; Weldegebriel Z; Legesse M
    BMC Res Notes; 2016 Apr; 9():206. PubMed ID: 27053243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.